Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF) (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Depreciation & Amortization (CF) of $121000.0 for Q1 2026, up 3.42% year-over-year from $117000.0 in Q1 2025, and up 0.83% quarter-over-quarter from $120000.0 in Q4 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $121000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 3.42% year-over-year to $121000.0; the TTM figure through Mar 2026 stood at $464000.0 (down 1.69% YoY), while the FY2025 annual figure was $460000.0, down 8.0% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $121000.0, up from $120000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $150000.0 in Q4 2023, with the low at $40000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $117000.0 (2025), against an average of $109294.1.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) soared 700.0% in 2022, then sank 44.67% in 2024.
- Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) stood at $96000.0 in 2022, then jumped by 56.25% to $150000.0 in 2023, then tumbled by 44.67% to $83000.0 in 2024, then jumped by 44.58% to $120000.0 in 2025, then rose by 0.83% to $121000.0 in 2026.
- Business Quant data shows VRDN's Depreciation & Amortization (CF) at $121000.0 in Q1 2026, $120000.0 in Q4 2025, and $110000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | 117,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 117,000.00 |
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Sep 30, 2025 | 110,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 117,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Mar 31, 2024 | 145,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Sep 30, 2023 | 135,000.00 |
| Jun 30, 2023 | 132,000.00 |
| Mar 31, 2023 | 105,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 62,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 30,000.00 |